Modified dsRNA Molecules for DDIT4 Knockdown
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid molecules for down-regulating DDIT4 expression lack improved bioavailability, biodistribution, serum stability, and specificity, leading to reduced efficacy in treating diseases associated with DDIT4 gene expression.
Innovation Solution
Development of chemically modified double-stranded nucleic acid molecules, such as siRNA and shRNA, that bind specifically to DDIT4 mRNA, incorporating modifications like 2'OMe sugar modifications and unconventional moieties to enhance serum stability, cellular uptake, and target specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If unmodified dsRNA molecules are used for down-regulating DDIT4 expression, then the molecular structure is simple and easy to manufacture, but the serum stability is poor and biodistribution is limited
Solution Approach 1:
The patent applies composite materials by combining dsRNA with chemically modified nucleosides and nucleotides (2'OMe modifications, unconventional moieties) to create a hybrid molecular structure that maintains RNAi functionality while gaining enhanced serum stability and resistance to nucleases, directly resolving the contradiction between simplicity and stability
Solution Approach 2:
The patent changes chemical parameters of the nucleic acid molecule by introducing 2'OMe sugar modifications and unconventional moieties at specific positions, which alters the molecular properties to improve serum stability, cellular uptake, and pharmacokinetic profile without completely changing the fundamental dsRNA structure
2Reliability
If unmodified dsRNA molecules are used, then the manufacturing process is simple, but the cellular uptake is insufficient and bioavailability is poor
Solution Approach 1:
The patent modifies chemical parameters including 2'OMe modifications and unconventional moieties to enhance cellular uptake and bioavailability, achieving reliable therapeutic efficacy while maintaining a manufacturing process that builds upon conventional oligonucleotide synthesis methods
Solution Approach 2:
The patent applies local quality by introducing modifications at specific positions (2'OMe at certain nucleotides, unconventional moieties at terminal positions) rather than uniform modification throughout the molecule, optimizing cellular uptake and stability while controlling manufacturing complexity
3Measurement precision
If standard dsRNA molecules are used, then the treatment approach is simple, but the off-target activity is high and specificity is low
Solution Approach 1:
The patent applies local quality by introducing unconventional moieties and 2'OMe modifications at specific terminal positions of the dsRNA molecule, which enhances target specificity and reduces off-target effects through improved binding affinity and reduced immunogenicity, while maintaining manageable molecular complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified nucleic acid molecules exhibit increased serum stability, improved cellular uptake, reduced off-target activity, and enhanced knockdown activity compared to unmodified counterparts, effectively treating conditions associated with DDIT4 expression.
Implementation Method 1
double-stranded nucleic acid molecules... that bind specifically to DDIT4 mRNA
Implementation Method 2
incorporating modifications like 2'OMe sugar modifications and unconventional moieties to enhance serum stability
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Provided herein are double stranded nucleic acid molecules, compositions comprising same and methods of use thereof for the treatment of a subject wherein expression of DDIT4 is associated with the etiology or progression of a disease or disorder in the subject. The compounds are preferably chemically synthesized and modified dsRNA molecules.